A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.
Aged
Aged, 80 and over
Female
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Immune Checkpoint Proteins
/ genetics
Male
Middle Aged
Molecular Targeted Therapy
/ adverse effects
Prognosis
Proportional Hazards Models
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ diagnosis
Survival Rate
Treatment Outcome
Head and neck cancer
Immunotherapy
Metastatic
PD-1 inhibitors
Predictors
Response
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
09
03
2020
revised:
04
07
2020
accepted:
07
07
2020
pubmed:
24
7
2020
medline:
10
7
2021
entrez:
24
7
2020
Statut:
ppublish
Résumé
ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments. This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.
Sections du résumé
BACKGROUND
ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments.
PATIENTS AND METHODS
This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.
Identifiants
pubmed: 32702630
pii: S1368-8375(20)30336-5
doi: 10.1016/j.oraloncology.2020.104900
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Immune Checkpoint Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104900Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.